Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer.

ABSTRACT:

Purpose

Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood.

Experimental design

All cases of metastatic lung cancer treated with PD-(L)1 blockade at Memorial Sloan Kettering were reviewed. In acquired resistance (complete/partial response per RECIST, followed by progression), clinical patterns were distinguished as oligo (OligoAR ≤ 3 lesions of disease progression) or systemic (sAR). We analyzed the relationships between patient characteristics, burden/location of disease, outcomes, and efficacy of therapeutic interventions.

Results

Of 1,536 patients, 312 (20%) had an initial response and 143 developed AR (9% overall, 46% of responders). OligoAR was the most common pattern (80/143, 56%). Baseline tu

SUBMITTER: Schoenfeld AJ 

PROVIDER: S-EPMC10448606 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature